The basis for K-Ras4B binding specificity to protein farnesyl- transferase revealed by 2 Å resolution ternary complex structures

Structure

Volumn 8, Issue 2, 2000, Pages 209-222

  Long, Stephen B ^a   Casey, Patrick J ^a   Beese, Lorena S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CaaX; Cancer; Crystal structure; Farnesyl transferase; Ras

Indexed keywords

MAGNESIUM ION; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHO FACTOR;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; PRIORITY JOURNAL; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TUMOR REGRESSION;

ANIMALIA;

EID: 0034651550     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(00)00096-4     Document Type: Article

References (51)

1. Gibbs J.B., Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 37:1997;143-166.
2. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:1996;241-269.
3. Strickland C.L., Ganguly A.K.et al. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J. Med. Chem. 42:1999;2125-2135.
4. Soignet S., Rowinsky E.et al. Pharmacokinetics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumors. Proc. Am. Assoc. Cancer Res. 40:1999;517.
5. Reiss Y., Goldstein J.L., Seabra M.C., Casey P.J., Brown M.S. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell. 62:1990;81-88.
6. Moomaw J.F., Casey P.J. Mammalian protein geranylgeranyltransferase: subunit composition and metal requirements. J. Biol. Chem. 267:1992;17438-17443.
7. Yokoyama K., Gelb M.H. Purification of a mammalian protein geranylgeranyltransferase: formation and catalytic properties of an enzyme-geranylgeranyl diphosphate complex. J. Biol. Chem. 268:1993;4055-4060.
8. Moores S.L., Gibbs J.B.et al. Sequence dependence of protein isoprenylation. J. Biol. Chem. 266:1991;14603-14610.
9. Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem. 61:1992;355-386.
10. Yokoyama K., Goodwin G.W., Ghomashchi F., Glomset J.A., Gelb M.H. A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proc. Natl Acad. Sci. USA. 88:1991;5302-5306.
11. Casey P.J., Thissen J.A., Moomaw J.F. Enzymatic modification of proteins with a geranylgeranyl isoprenoid. Proc. Natl Acad. Sci. USA. 88:1991;8631-8635.
12. Reiss Y., Brown M.S., Goldstein J.L. Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme. J. Biol. Chem. 267:1992;6403-6408.
13. Chen W.-J., Moomaw J.F., Overton L., Kost T.A., Casey P.J. High-level expression of mammalian protein farnesyltransferase in a baculovirus system: the purified protein contains zinc. J. Biol. Chem. 268:1993;9675-9680.
14. Zhang F.L., Moomaw J.F., Casey P.J. Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type I. J. Biol. Chem. 269:1994;23465-23470.
15. 2+-FTase indicates metal coordination of the substrate thiolate. J. Biol. Chem. 272:1997;20-23.
16. Strickland C.L., Weber P.C.et al. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry. 37:1998;16601-16611.
17. Pompliano D.L., Gibbs J.B.et al. Isoprenoid diphosphate utilization by recombinant human farnesyl:protein transferase: interactive binding between substrates and a preferred kinetic pathway. Biochemistry. 32:1993;8341-8347.
18. Furfine E.S., Leban J.J., Landavazo A., Moomaw J.F., Casey P.J. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry. 34:1995;6857-6862.
19. Dolence J.M., Poulter C.D. A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase. Proc. Natl Acad. Sci. USA. 92:1995;5008-5011.
20. Cassidy P.B., Poulter C.D. Transition state analogs for protein farnesyltransferase. J. Am. Chem. Soc. 118:1996;8761-8762.
21. Park H.-W., Boduluri S.R., Moomaw J.F., Casey P.J., Beese L.S. Crystal structure of protein farnesyltransferase at 2.25 Å resolution. Science. 275:1997;1800-1804.
22. Dunten P., Birktoft J.et al. Protein farnesyltransferase: structure and implications for substrate binding [published erratum appears in Biochemistry 1998 Sep 15;37(37):13042]. Biochemistry. 37:1998;7907-7912.
23. Long S., Casey P.J., Beese L.S. Co-crystal structure of mammalian protein farnesyltransferase with a farnesyl diphosphate substrate. Biochemistry. 37:1998;9612-9618.
24. Stradley S.J., Rizo J., Gierasch L.M. Conformation of a heptapeptide substrate bound to protein farnesyltransferase. Biochemistry. 32:1993;12586-12590.
25. Koblan K.S., Bogusky M.J.et al. NMR studies of novel inhibitors bound to farnesyl-protein transferase. Protein Sci. 4:1995;681-688.
26. James G.L., Goldstein J.L., Brown M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270:1995;6221-6226.
27. Hancock J.F., Paterson H., Marshall C.J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell. 63:1990;133-139.
28. Ghomashchi F., Zhang X., Liu L., Gelb M.H. Binding of prenylated and polybasic peptides to membranes: affinities and intervesicle exchange. Biochemistry. 34:1995;11910-11918.
29. Barbacid M. ras genes. Annu. Rev. Biochem. 56:1987;779-827.
30. Zhang F.L., Bishop W.R.et al. Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem. 272:1997;10232-10239.
31. Reiss Y., Brown M.S. Nonidentical subunits of p21 H-ras farnesyltransferase: peptide binding and farnesyl pyrophosphate carrier functions. J. Biol. Chem. 266:1991;10672-10677.
32. Ying W., Sepp-Lorenzino L., Cai K., Aloise P., Coleman P.S. Photoaffinity-labeling peptide substrates for farnesyl-protein transferase and the intersubunit location of the active site. J. Biol. Chem. 269:1994;470-477.
33. Kral A.M., Omer C.A.et al. Mutational analysis of conserved residues of the beta-subunit of human farnesyl:protein transferase. J. Biol. Chem. 272:1997;27319-27323.
34. Reiss Y., Stradley S.J., Gierasch L.M., Brown M.S., Goldstein J.L. Sequence requirements for peptide recognition by rat brain p21ras farnesyl:protein transferase. Proc. Natl Acad. Sci. USA. 88:1991;732-736.
35. Andres D.A., Goldstein J.L., Ho Y.K., Brown M.S. Mutational analysis of α-subunit of protein farnesyltransferase. J. Biol. Chem. 268:1993;1383-1390.
36. Roskoski R. Jr., Ritchie P. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase. Arch. Biochem. Biophys. 356:1998;167-176.
37. Trueblood C.E., Ohya Y., Rine J. Genetic evidence for in vivo cross-specificity of the CaaX-Box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol. Cell. Biol. 13:1993;4260-4275.
38. Whyte D.B., Pai J.K.et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272:1997;14459-14464.
39. Rowell C.A., Kowalczyk J.J., Lewis M.D., Garcia A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272:1997;14093-14097.
40. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta. 1333:1997;F51-F71.
41. Goldstein J.L., Brown M.S., Stradley S.J., Reiss Y., Geirasch L.M. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J. Biol. Chem. 266:1991;15575-15578.
42. Brown M.S., Goldstein J.L., Paris K.J., Burnier J.P., Marsters J.C. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitutions in phenylalanine-containing tetrapeptides restores farnesylation. Proc. Natl Acad. Sci. USA. 89:1992;8313-8316.
43. Manne V., Biller S.A.et al. Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Dev. Res. 34:1995;121-137.
44. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276A:1997;307-326.
45. Brünger A.T. X-PLOR version 3.1: A System for X-ray Crystallography and NMR. 1992;Yale University Press, New Haven, CT, USA.
46. Brünger A.T., Jiang J.S. Protein hydration observed by X-ray diffraction: solution properties of penicillopepsin and neuraminidase crystal structures. J. Mol. Biol. 243:1994;100-115.
47. Jones T.A., Kjeldgaard M. O version 5.9, The manual. 1993;Uppsala University, Uppsala, Sweden.
48. Word J.M., Richardson D.C.et al. Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms. J. Mol. Biol. 285:1999;1711-1733.
49. Collaborative Computational Project No. 4. Acta Crystallogr. D. 50:1994;760.
50. Carson M. Ribbon models of macromolecules. J. Mol. Graph. 5:1987;103-106.
51. Nicholls A. GRASP: Graphical Representation and Analysis of Surface Properties. 1992;Columbia University Press, New York, New York.